SAB Biotherapeutics's total assets for Q3 2024 were $53.80M, a decrease of -13.08% from the previous quarter. SABS total liabilities were $16.89M for the fiscal quarter, a 7.12% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.